Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp and Waters announced a partnership to offer the FDA-approved BD Onclarity HPV Assay across Labcorp's nationwide network beginning in late 2026, with Labcorp intending to be the first commercial lab to offer it across clinician-collected and self-collected settings. The assay is the only FDA-approved HPV test supporting all ASCCP risk-based guidelines, with extended genotyping of types 16, 18, 31, 45, 51 and 52 plus pooled results. Labcorp will distribute the test through its network of 850,000+ providers, 2,200+ patient service centers, health plan programs, and the Labcorp OnDemand consumer channel, supporting women's health revenue growth.
Key figures
- Launch timing
- late 2026
- Physicians served
- more than 850,000
- Patient service centers
- more than 2,200
- Genotypes individually identified
- 6 (types 16, 18, 31, 45, 51, 52)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.